0001000228-23-000026 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover Page - shares	3 Months Ended
Cover Page - shares	Apr. 01, 2023	May 01, 2023
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-30
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 01, 2023
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		131,003,202

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Apr. 01, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 126	$ 117
Accounts receivable, net of allowances for credit losses of $65 and $65	1,470	1,442
Inventories, net	1,918	1,963
Prepaid expenses and other	438	466
Total current assets	3,952	3,988
Property and equipment, net	396	383
Operating lease right-of-use assets	280	284
Goodwill	2,917	2,893
Other intangibles, net	548	587
Investments and other	479	472
Total assets	8,572	8,607
Current liabilities:
Accounts payable	855	1,004
Bank credit lines	236	103
Current maturities of long-term debt	55	6
Operating lease liabilities	73	73
Accrued expenses:
Payroll and related	231	314
Taxes	156	132
Other	566	592
Total current liabilities	2,172	2,224
Long-term debt	1,021	1,040
Deferred income taxes	40	36
Operating lease liabilities	274	275
Other liabilities	368	361
Total liabilities	3,875	3,936
Redeemable noncontrolling interests	570	576
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $0.01 par value, 480,000,000 shares authorized, 131,196,783 outstanding on April 01, 2023 and 131,792,817 outstanding on December 31, 2022	1	1
Additional paid-in capital	0	0
Retained earnings	3,684	3,678
Accumulated other comprehensive loss	(213)	(233)
Total Henry Schein, Inc. stockholders' equity	3,472	3,446
Noncontrolling interests	655	649
Total stockholders' equity	4,127	4,095
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 8,572	$ 8,607

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Apr. 01, 2023	Dec. 31, 2022
Current assets:
Accounts receivable, allowances for credit losses (in dollars)	$ 65	$ 65
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	131,196,783	131,792,817

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)	3 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)	Apr. 01, 2023	Mar. 26, 2022
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract]
Net sales	$ 3,060,000,000	$ 3,179,000,000
Cost of sales	2,094,000,000	2,206,000,000
Gross profit	966,000,000	973,000,000
Operating expenses:
Selling, general and administrative	717,000,000	682,000,000
Depreciation and amortization	44,000,000	47,000,000
Restructuring costs	30,000,000	0
Operating income	175,000,000	244,000,000
Other income (expense):
Interest income	3,000,000	2,000,000
Interest expense	(14,000,000)	(7,000,000)
Other, net	(1,000,000)	0
Income before taxes, equity in earnings of affiliates and noncontrolling interests	163,000,000	239,000,000
Income taxes	(39,000,000)	(57,000,000)
Equity in earnings of affiliates	4,000,000	4,000,000
Net income	128,000,000	186,000,000
Less: Net income attributable to noncontrolling interests	(7,000,000)	(5,000,000)
Net income attributable to Henry Schein, Inc.	$ 121,000,000	$ 181,000,000
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 0.92	$ 1.31
Diluted (in dollars per share)	$ 0.91	$ 1.30
Weighted-average common shares outstanding:
Basic (in shares)	131,365,789	137,296,581
Diluted (in shares)	133,039,886	139,237,472

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]
Net income	$ 128	$ 186
Other comprehensive income, net of tax:
Foreign currency translation gain	25	3
Unrealized gain (loss) from foreign currency hedging activities	(3)	1
Other comprehensive income, net of tax	22	4
Comprehensive income	150	190
Less: Comprehensive income attributable to noncontrolling interests:
Net income	(7)	(5)
Foreign currency translation gain	(2)	(1)
Comprehensive income attributable to noncontrolling interests	(9)	(6)
Comprehensive income attributable to Henry Schein, Inc.	$ 141	$ 184

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock $.01 Par Value [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 25, 2021	$ 4,063	$ 1	$ 0	$ 3,595	$ (171)	$ 638
Beginning Balance, shares (in shares) at Dec. 25, 2021		137,145,558
Net income (excluding amounts attributable to redeemable noncontrolling interests)	182	$ 0	0	181	0	1
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	2	0	0	0	2	0
Unrealized gain from foreign currency hedging activities, net of tax	1	0	0	0	1	0
Purchase of noncontrolling interests	(7)	0	0	0	0	(7)
Change in fair value of redeemable securities	(3)	0	(3)	0	0	0
Stock-based compensation expense - Value	12	$ 0	12	0	0	0
Stock-based compensation expense - Shares		876,161
Stock issued upon exercise of stock options - Value	2	$ 0	2	0	0	0
Stock issued upon exercise of stock options - Shares		26,233
Shares withheld for payroll taxes - Value	(28)	$ 0	(28)	0	0	0
Shares withheld for payroll taxes - Shares		(336,331)
Settlement of stock-based compensation awards - Value	0	$ 0	0	0	0	0
Settlement of stock-based compensation awards - Shares		(2,812)
Transfer of charges in excess of capital	0	$ 0	17	(17)	0	0
Ending Balance at Mar. 26, 2022	4,224	$ 1	0	3,759	(168)	632
Ending Balance, shares (in shares) at Mar. 26, 2022		137,708,809
Beginning Balance at Dec. 31, 2022	$ 4,095	$ 1	0	3,678	(233)	649
Beginning Balance, shares (in shares) at Dec. 31, 2022	131,792,817	131,792,817
Net income (excluding amounts attributable to redeemable noncontrolling interests)	$ 124	$ 0	0	121	0	3
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	23	0	0	0	23	0
Unrealized gain from foreign currency hedging activities, net of tax	(3)	0	0	0	(3)	0
Change in fair value of redeemable securities	3	0	3	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	3	0	0	0	0	3
Repurchases and retirement of common stock - Value	(100)	$ 0	(13)	(87)	0	0
Repurchases and retirement of common stock - Shares		(1,223,919)
Stock-based compensation expense - Value	10	$ 0	10	0	0	0
Stock-based compensation expense - Shares		1,016,300
Stock issued upon exercise of stock options - Value	$ 1	$ 0	1	0	0	0
Stock issued upon exercise of stock options - Shares	10,897	10,779
Shares withheld for payroll taxes - Value	$ (29)	$ 0	(29)	0	0	0
Shares withheld for payroll taxes - Shares		(399,194)
Transfer of charges in excess of capital	0	$ 0	28	(28)	0	0
Ending Balance at Apr. 01, 2023	$ 4,127	$ 1	$ 0	$ 3,684	$ (213)	$ 655
Ending Balance, shares (in shares) at Apr. 01, 2023	131,196,783	131,196,783

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Apr. 01, 2023	Mar. 26, 2022	Dec. 31, 2022
Net income attributable to redeemable noncontrolling interests	$ 4	$ 4	$ 21
Foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	2	1	$ (6)
Unrealized gain from foreign currency hedging activities, tax	$ (1)	$ 1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Cash flows from operating activities:
Net income	$ 128	$ 186
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	52	55
Non-cash restructuring charges	7	0
Stock-based compensation expense	10	12
Provision for losses on trade and other accounts receivable	1	1
Provision for (benefit from) deferred income taxes	2	(3)
Equity in earnings of affiliates	(4)	(4)
Distributions from equity affiliates	2	4
Changes in unrecognized tax benefits	1	4
Other	(1)	(7)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(20)	16
Inventories	63	(9)
Other current assets	29	26
Accounts payable and accrued expenses	(243)	(188)
Net cash provided by operating activities	27	93
Cash flows from investing activities:
Purchases of fixed assets	(31)	(19)
Payments related to equity investments and business acquisitions, net of cash acquired	(1)	(5)
Proceeds from loan to affiliate	2	4
Other	(9)	(7)
Net cash used in investing activities	(39)	(27)
Cash flows from financing activities:
Net change in bank borrowings	132	30
Proceeds from issuance of long-term debt	31	0
Principal payments for long-term debt	(1)	(53)
Proceeds from issuance of stock upon exercise of stock options	1	2
Payments for repurchases and retirement of common stock	(100)	0
Payments for taxes related to shares withheld for employee taxes	(30)	(26)
Distributions to noncontrolling shareholders	(4)	(5)
Acquisitions of noncontrolling interests in subsidiaries	(8)	(10)
Net cash provided by (used in) financing activities	21	(62)
Effect of exchange rate changes on cash and cash equivalents	0	4
Net change in cash and cash equivalents	9	8
Cash and cash equivalents, beginning of period	117	118
Cash and cash equivalents, end of period	$ 126	$ 126

Basis of Presentation	3 Months Ended
Basis of Presentation	Apr. 01, 2023
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our condensed consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries (“we”, “us” or “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates in which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our condensed consolidated financial condition, results of operations or cash flows. Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022 and with the information contained in our other publicly- available filings with the Securities and Exchange Commission. The condensed consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three months ended April 1, 2023 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 30, 2023. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At April 1, 2023 and December 31, 2022, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 555 million and $ 327 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 420 million and $ 255 million, respectively. Our condensed consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. There is an ongoing risk that the consequences of the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards	3 Months Ended
	Apr. 01, 2023
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards [Abstract]
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards	Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards Critical Accounting Policies There have been no material changes in our critical accounting policies during the three months ended April 1, 2023, as compared to the critical accounting policies described in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022. Recently Issued Accounting Standards In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations,” which will increase transparency of supplier finance programs by requiring entities that use such programs in connection with the purchase of goods and services to disclose certain qualitative and quantitative information about such programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for amended roll forward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect that the requirements of this guidance will have a material impact on our condensed consolidated financial statements. In December 2022, the FASB issued ASU No. 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” which extends the period of application of temporary optional expedients from December 21, 2022 to December 31, 2024. We do not expect that the requirements of this guidance will have a material impact on our condensed consolidated financial statements.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI https://asc.fasb.org/topic&trid=2122394

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

+ Details

Net Sales from Contracts with Customers	3 Months Ended
Net Sales from Contracts with Customers	Apr. 01, 2023
Net Sales from Contracts with Customers [Abstract]
Net sales from Contracts with Customers	Note 3 – Net Sales from Contracts with Customers Net sales are recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2022. Disaggregation of Net Sales The following table disaggregates our net sales by reportable segment and geographic area: Three Months Ended April 1, 2023 North America International Global Net sales: Health care distribution Dental $ 1,144 $ 754 $ 1,898 Medical 951 20 971 Total health care distribution 2,095 774 2,869 Technology and value-added services 166 25 191 Total net sales $ 2,261 $ 799 $ 3,060 Three Months Ended March 26, 2022 North America International Global Net sales: Health care distribution Dental $ 1,105 $ 723 $ 1,828 Medical 1,150 22 1,172 Total health care distribution 2,255 745 3,000 Technology and value-added services 156 23 179 Total net sales $ 2,411 $ 768 $ 3,179 Deferred Revenue During the three months ended April 1, 2023, we recognized in net sales $ 35 million of the amounts that were previously deferred at December 31, 2022. At December 31, 2022, the current portion of contract liabilities of $ 86 million was reported in accrued expenses: other, and $ 8 million related to non-current contract liabilities was reported in other liabilities. At April 1, 2023, the current and non-current portion of contract liabilities were $ 85 million and $ 9 million, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Segment Data	3 Months Ended
Segment Data	Apr. 01, 2023
Segment Data [Abstract]
Segment Data	Note 4 – Segment Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices and integrated delivery networks, among other providers across a wide range of specialties. Our dental and medical groups serve practitioners in 32 countries worldwide. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, dental specialty products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment (“PPE”) and vitamins. Our global technology and value-added services reportable segment provides software, technology and other value- added services to health care practitioners. Our technology offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The following tables present information about our reportable and operating segments: Three Months Ended April 1, March 26, 2023 2022 Net Sales: Health care distribution (1) Dental $ 1,898 $ 1,828 Medical 971 1,172 Total health care distribution 2,869 3,000 Technology and value-added services (2) 191 179 Total $ 3,060 $ 3,179 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Three Months Ended April 1, March 26, 2023 2022 Operating Income: Health care distribution $ 145 $ 211 Technology and value-added services 30 33 Total $ 175 $ 244

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Business Acquisitions	3 Months Ended
Business Acquisitions	Apr. 01, 2023
Business Acquisitions [Abstract]
Business Acquisitions	Note 5 – Business Acquisitions In connection with our business acquisitions, the major classes of assets and liabilities to which we generally allocate acquisition consideration to, excluding goodwill, include identifiable intangible assets (i.e., customer relationships and lists, trademarks and trade names, product development and non-compete agreements), inventory and accounts receivable. The estimated fair value of identifiable intangible assets is based on critical judgments and assumptions derived from analysis of market conditions, including discount rates, projected revenue growth rates (which are based on historical trends and assessment of financial projections), estimated customer attrition and projected cash flows. These assumptions are forward-looking and could be affected by future economic and market conditions. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, within 12 months following the date of acquisition, or the measurement period, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our condensed consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our condensed consolidated statements of operations. The accounting for certain of our acquisitions during the year ended December 31, 2022 had not been completed in several areas, including but not limited to pending assessments of intangible assets, and contingent consideration assets and liabilities. For the three months ended April 1, 2023 and March 26, 2022, there were no material adjustments recorded in our condensed consolidated statements of income relating to changes in estimated values of assets acquired, liabilities assumed and contingent consideration assets and liabilities. 2023 Acquisitions During the three months ended April 1, 2023, we acquired the majority of a company within the health care distribution segment. The impact of this acquisition was not considered material to our condensed consolidated financial statements. The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for the acquisition during the three months ended April 1, 2023. 2023 Acquisition consideration: Cash $ 8 Deferred consideration 1 Noncontrolling interests 2 Total consideration $ 11 Intangible assets $ 2 Total identifiable net assets 2 Goodwill 9 Total net assets acquired $ 11 The acquired goodwill is deductible for tax purposes. During the three months ended April 1, 2023 the identifiable intangible assets acquired consisted of customer relationships and lists of $ 1 million and trademarks and tradenames of $ 1 million. The estimated useful lives of these intangible assets are 2 years and 5 years , respectively. Acquisition Costs During the three months ended April 1, 2023 and March 26, 2022 we incurred $ 7 million and $ 1 million, respectively, in acquisition costs.

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Apr. 01, 2023
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 6 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable. Certain of our notes receivable contain variable interest rates. We believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Debt The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is classified as Level 3 within the fair value hierarchy, and as of April 1, 2023 and December 31, 2022 was estimated at $ 1,312 million and $ 1,149 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental executive retirement plan and our deferred compensation plan. The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. Total Return Swaps The fair value for the total return swap is measured by valuing the underlying exchange traded funds of the swap using market-on-close pricing by industry providers as of the valuation date and are classified within Level 2 of the fair value hierarchy. Redeemable noncontrolling interests The values for redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. Assets measured on a non-recurring basis at fair value include Goodwill and Other intangibles, net, and are classified as Level 3 within the fair value hierarchy. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of April 1, 2023 and December 31, 2022: April 1, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 19 $ - $ 19 Derivative contracts undesignated - 3 - 3 Total return swaps - 1 - 1 Total assets $ - $ 23 $ - $ 23 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 3 $ - $ 3 Redeemable noncontrolling interests $ - $ - $ 570 $ 570 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return swaps - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576

Debt	3 Months Ended
Debt	Apr. 01, 2023
Debt [Abstract]
Debt	Note 7 – Debt Bank Credit Lines Bank credit lines consisted of the following: April 1, December 31, 2023 2022 Revolving credit agreement $ - $ - Other short-term bank credit lines 236 103 Total $ 236 $ 103 Revolving Credit Agreement On August 20, 2021 , we entered into a $ 1.0 billion revolving credit agreement (the “Credit Agreement”). This facility, which matures on August 20, 2026 replaced our $ 750 million revolving credit facility which was scheduled to mature in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. Most LIBOR rates have been discontinued after December 31, 2021, while the remaining LIBOR rates will be discontinued immediately after June 30, 2023. We do not expect the discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our financial position or to materially affect our interest expense. The Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of April 1, 2023 and December 31, 2022, we had no borrowings under this revolving credit facility, and there were $ 9 million and $ 9 million of letters of credit, respectively, provided to third parties under the credit facility. Other Short-Term Bank Credit Lines As of April 1, 2023 and December 31, 2022, we had various other short-term bank credit lines available, with a maximum borrowing capacity of $ 404 million and $ 402 million, respectively. As of April 1, 2023 and December 31, 2022, $ 236 million and $ 103 million, respectively, were outstanding. At April 1, 2023 and December 31, 2022, borrowings under all of these credit lines had a weighted average interest rate of 7.55 % and 10.11 %, respectively. Long-term debt Long-term debt consisted of the following: April 1, December 31, 2023 2022 Private placement facilities $ 699 $ 699 U.S. trade accounts receivable securitization 360 330 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 3.65 % at April 1, 2023 and ranging from 0.00 % to 3.50 % at December 31, 2022 8 7 Finance lease obligations 9 10 Total 1,076 1,046 Less current maturities (55) (6) Total long-term debt $ 1,021 $ 1,040 Private Placement Facilities Our private placement facilities include four insurance companies, have a total facility amount of $ 1.5 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through October 20, 2026 . The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years ). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. The components of our private placement facility borrowings, which have a weighted average interest rate of 2.99 %, as of April 1, 2023 are presented in the following table: Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 Less: Deferred debt issuance costs (1) Total $ 699 U.S. Trade Accounts Receivable Securitization We have a facility agreement based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . This facility agreement has a purchase limit of $ 450 million with two banks as agents, expires on December 15, 2025 . As of April 1, 2023 and December 31, 2022, the borrowings outstanding under this securitization facility were $ 360 million and $ 330 million, respectively. At April 1, 2023, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 4.99 % plus 0.75 %, for a combined rate of 5.74 %. At December 31, 2022, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 4.58 % plus 0.75 %, for a combined rate of 5.33 %. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes	3 Months Ended
Income Taxes	Apr. 01, 2023
Income Taxes [Abstract]
Income Taxes	Note 8 – Income Taxes For the three months ended April 1, 2023 our effective tax rate was 23.8 % compared to 24.0 % for the prior year period. The difference between our effective tax rate and the federal statutory tax rate primarily relates to state and foreign income taxes and interest expense as well as stock-based compensation. The total amount of unrecognized tax benefits, which are included in “other liabilities” within our condensed consolidated balance sheets, as of April 1, 2023 and December 31, 2022 was $ 95 million and $ 94 million, respectively, of which $ 80 million and $ 80 million, respectively, would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our condensed consolidated statements of income. All tax returns audited by the IRS are officially closed through 2018. The tax years subject to examination by the IRS include years 2019 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS examination. During the quarter ended December 25, 2021, we were notified by the IRS that tax year 2019 was selected for examination. The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense was $ 1 million for the three months ended April 1, 2023 and $ 1 million for the three months ended March 26, 2022. The total amount of accrued interest is included in “other liabilities,” and was $ 13 million as of April 1, 2023 and $ 12 million as of December 31, 2022. The amount of penalties accrued for during the periods presented were not material to our condensed consolidated financial statements

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Plan of Restructuring	3 Months Ended
Plan of Restructuring	Apr. 01, 2023
Plan of Restructuring [Abstract]
Plan of Restructuring	Note 9 – Plan of Restructuring On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the strategic plan and streamlining operations and other initiatives to increase efficiency. We expect this initiative to extend through 2023. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. During the three months ended April 1, 2023, we recorded restructuring costs of $ 30 million primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other lease exit costs. This amount also includes $ 1 million related to the disposal of an unprofitable U.S. business, initiated during 2022 and completed during the three months ended April 1, 2023. Restructuring costs recorded for the three months ended April 1, 2023 consisted of the following (there were no restructuring costs for the three months ended March 26, 2022): Three Months Ended April 1, 2023 Health-Care Distribution Technology and Value-Added Services Total Severance and employee-related costs $ 17 $ 3 $ 20 Accelerated depreciation and amortization 7 - 7 Exit and other related costs 1 1 2 Loss on disposal of a business 1 - 1 Total restructuring costs $ 26 $ 4 $ 30 The following table summarizes, by reportable segment, the activity related to the liabilities associated with our restructuring initiatives for the period ended April 1, 2023. The remaining accrued balance of restructuring costs as of April 1, 2023 is included in accrued expenses: other within our condensed consolidated balance sheet. Technology and Health Care Value-Added Distribution Services Total Balance, December 31, 2022 $ 21 $ 3 $ 24 Restructuring costs 26 4 30 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (7) - (7) Cash payments and other adjustments (14) (3) (17) Balance, April 1, 2023 $ 26 $ 4 $ 30

Legal Proceedings	3 Months Ended
Legal Proceedings	Apr. 01, 2023
Legal Proceedings [Abstract]
Legal Proceedings	Note 10 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one- hundred and seventy-five ( 175 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its affiliated companies) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following cases are set for trial: the action filed by DCH Health Care Authority, et al. in Alabama state court, which has been designated a bellwether with eight of thirty-eight plaintiffs set for a jury trial on July 24, 2023; and the action filed by Florida Health Sciences Center, Inc. (and 38 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in May 2025. Of Henry Schein’s 2022 net sales of approximately $ 12.6 billion from continuing operations, sales of opioids represented less than two-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia, seeking documents in connection with an investigation of possible violations of the Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia. The October Subpoena seeks documents relating to payments Henry Schein received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the investigation. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of April 1, 2023, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Apr. 01, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 11 – Stock-Based Compensation Stock-based awards are provided to certain employees under the terms of our 2020 Stock Incentive Plan and to non-employee directors under the terms of our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”) with the exception of our 2021 plan year in which non-qualified stock options were issued in place of performance-based RSUs. In 2022, we granted time- based and performance-based RSUs, as well as non-qualified stock options. For our 2023 plan year, we returned to granting our employees equity-based awards solely in the form of time-based and performance-based RSUs. Our non-employee directors receive equity-based awards solely in the form of time-based RSUs. RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that primarily vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. RSUs granted to our non-employee directors primarily are granted with 12 -month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line basis. With respect to time-based RSUs, we estimate the fair value based on our closing stock price on the date of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant. Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2020 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital transactions referred to above), restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact either positive or negative, of the difference in projected earnings generated by COVID-19 test kits (solely with respect to performance-based RSUs granted in the 2022 and 2023 plan years) and impairment charges (solely with respect to performance-based RSUs granted in the 2023 plan year), and unforeseen events or circumstances affecting us. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans. Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price following vesting of the stock options. Stock options were granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued in 2021 and 2022 vest one-third per year based on the recipient’s continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of the term upon certain events. Compensation expense for these stock options is recognized using a graded vesting method. We estimated the fair value of stock options using the Black-Scholes valuation model. During the three months ended April 1, 2023 we did no t grant any stock options. Our accompanying condensed consolidated statements of income reflect pre-tax share-based compensation expense of $ 10 million ($ 7 million after-tax) and $ 12 million ($ 9 million after-tax) for the three months ended April 1, 2023 and March 26, 2022, respectively. Total unrecognized compensation cost related to unvested awards as of April 1, 2023 was $ 119 million, which is expected to be recognized over a weighted average period of approximately 2.7 years. Our accompanying condensed consolidated statements of cash flows present our stock-based compensation expense as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, there were no benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the three months ended April 1, 2023 and March 26, 2022, respectively. We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The six -year expected life of the options was determined using the simplified method for estimating the expected term as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us. The following table summarizes the stock option activity during the three months ended April 1, 2023: Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,117,574 $ 71.38 Granted - - Exercised (10,897) 62.71 Forfeited (5,911) 77.31 Outstanding at end of period 1,100,766 $ 71.44 8.3 $ 13 Options exercisable at end of period 572,132 $ 68.11 Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 520,781 $ 75.22 8.5 $ 4 The following tables summarize the activity of our unvested RSUs for the three months ended April 1, 2023: Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,756,044 $ 66.59 520,916 $ 60.23 Granted 395,750 77.75 465,260 79.66 Vested (387,302) 61.13 (627,596) 60.66 Forfeited (34,843) 68.16 (39,463) 74.48 Outstanding at end of period 1,729,649 $ 70.38 $ 81.54 319,117 $ 68.96 $ 81.54

Redeemable Noncontrolling Interests	3 Months Ended
Redeemable Noncontrolling Interests	Apr. 01, 2023
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 12 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the three months ended April 1, 2023 and the year ended December 31, 2022 are presented in the following table: April 1, December 31, 2023 2022 Balance, beginning of period $ 576 $ 613 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (8) (31) Increase in redeemable noncontrolling interests due to business acquisitions 3 4 Net income attributable to redeemable noncontrolling interests 4 21 Dividends declared (4) (21) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests 2 (6) Change in fair value of redeemable securities (3) (4) Balance, end of period $ 570 $ 576

Comprehensive Income	3 Months Ended
Comprehensive Income	Apr. 01, 2023
Comprehensive Income [Abstract]
Comprehensive Income	Note 13 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: April 1, December 31, 2023 2022 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (35) $ (37) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (213) $ (236) Unrealized gain from foreign currency hedging activities 2 5 Pension adjustment loss (2) (2) Accumulated other comprehensive loss $ (213) $ (233) Total Accumulated other comprehensive loss $ (249) $ (271) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: Three Months Ended April 1, March 26, 2023 2022 Net income $ 128 $ 186 Foreign currency translation gain 25 3 Tax effect - - Foreign currency translation gain 25 3 Unrealized gain (loss) from foreign currency hedging activities (4) 2 Tax effect 1 (1) Unrealized gain (loss) from foreign currency hedging activities (3) 1 Comprehensive income $ 150 $ 190 Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain during the three months ended April 1, 2023 and three months ended March 26, 2022 was primarily due to changes in foreign currency exchange rates of the Euro, British Pound, Australian Dollar, Brazilian Real, New Zealand Dollar and Canadian Dollar. The following table summarizes our total comprehensive income, net of applicable taxes as follows: Three Months Ended April 1, March 26, 2023 2022 Comprehensive income attributable to Henry Schein, Inc. $ 141 $ 184 Comprehensive income attributable to noncontrolling interests 3 1 Comprehensive income attributable to Redeemable noncontrolling interests 6 5 Comprehensive income $ 150 $ 190

Earnings Per Share	3 Months Ended
Earnings Per Share	Apr. 01, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 14 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted- average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Three Months Ended April 1, March 26, 2023 2022 Basic 131,365,789 137,296,581 Effect of dilutive securities: Stock options and restricted stock units 1,674,097 1,940,891 Diluted 133,039,886 139,237,472 The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows: Three Months Ended April 1, March 26, 2023 2022 Stock options 422,190 76,597 Restricted stock units 18,305 70,923 Total anti-dilutive securities excluded from EPS computation 440,495 147,520

Supplemental Cash Flow Information	3 Months Ended
Supplemental Cash Flow Information	Apr. 01, 2023
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 15 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Three Months Ended April 1, March 26, 2023 2022 Interest $ 13 $ 8 Income taxes 21 21 During the three months ended April 1, 2023 and March 26, 2022, we had $ (4) million and $ 2 million of non-cash net unrealized gains (losses) related to foreign currency hedging activities, respectively.

Related Party Transactions	3 Months Ended
Related Party Transactions	Apr. 01, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 16 – Related Party Transactions In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $ 31 million annually for the use of their intellectual property. During the three months ended April 1, 2023 and March 26, 2022, we recorded $ 8 million and $ 9 million, respectively, in connection with costs related to this royalty agreement. As of April 1, 2023 and December 31, 2022, Henry Schein One, LLC had a net payable balance due to Internet Brands of $ 12 million and $ 8 million, respectively, comprised of amounts related to results of operations and the royalty agreement. The components of this payable are recorded within accrued expenses: other, within our condensed consolidated balance sheets. During our normal course of business, we have interests in entities that we account for under the equity accounting method. During the three months ended April 1, 2023 and March 26, 2022, we recorded net sales of $ 8 million and $ 12 million, respectively, to such entities. During the three months ended April 1, 2023 and March 26, 2022, we purchased $ 2 million and $ 4 million, respectively from such entities. At April 1, 2023 and December 31, 2022, we had an aggregate of $ 34 million and $ 36 million, respectively, due from our equity affiliates, and $ 6 million and $ 6 million, respectively, due to our equity affiliates.

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards (Policy)	3 Months Ended
	Apr. 01, 2023
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards [Abstract]
Accounting Pronouncements Adopted and Recently Issued Accounting Standards	Recently Issued Accounting Standards In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations,” which will increase transparency of supplier finance programs by requiring entities that use such programs in connection with the purchase of goods and services to disclose certain qualitative and quantitative information about such programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for amended roll forward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect that the requirements of this guidance will have a material impact on our condensed consolidated financial statements. In December 2022, the FASB issued ASU No. 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” which extends the period of application of temporary optional expedients from December 21, 2022 to December 31, 2024. We do not expect that the requirements of this guidance will have a material impact on our condensed consolidated financial statements.

Net Sales from Contracts with Customers (Tables)	3 Months Ended
Net Sales from Contracts with Customers (Tables)	Apr. 01, 2023
Net Sales from Contracts with Customers [Abstract]
Disaggregation of Revenue	Three Months Ended April 1, 2023 North America International Global Net sales: Health care distribution Dental $ 1,144 $ 754 $ 1,898 Medical 951 20 971 Total health care distribution 2,095 774 2,869 Technology and value-added services 166 25 191 Total net sales $ 2,261 $ 799 $ 3,060 Three Months Ended March 26, 2022 North America International Global Net sales: Health care distribution Dental $ 1,105 $ 723 $ 1,828 Medical 1,150 22 1,172 Total health care distribution 2,255 745 3,000 Technology and value-added services 156 23 179 Total net sales $ 2,411 $ 768 $ 3,179

Segment Data (Tables)	3 Months Ended
Segment Data (Tables)	Apr. 01, 2023
Segment Data [Abstract]
Business segment information	Three Months Ended April 1, March 26, 2023 2022 Net Sales: Health care distribution (1) Dental $ 1,898 $ 1,828 Medical 971 1,172 Total health care distribution 2,869 3,000 Technology and value-added services (2) 191 179 Total $ 3,060 $ 3,179 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Three Months Ended April 1, March 26, 2023 2022 Operating Income: Health care distribution $ 145 $ 211 Technology and value-added services 30 33 Total $ 175 $ 244

Business Acquisitions (Tables)	3 Months Ended
Business Acquisitions (Tables)	Apr. 01, 2023
Business Acquisitions [Abstract]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2023 Acquisition consideration: Cash $ 8 Deferred consideration 1 Noncontrolling interests 2 Total consideration $ 11 Intangible assets $ 2 Total identifiable net assets 2 Goodwill 9 Total net assets acquired $ 11

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Apr. 01, 2023
Fair Value Measurements [Abstract]
Fair value - assets and liabilities measured and recognized on a recurring basis	April 1, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 19 $ - $ 19 Derivative contracts undesignated - 3 - 3 Total return swaps - 1 - 1 Total assets $ - $ 23 $ - $ 23 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 3 $ - $ 3 Redeemable noncontrolling interests $ - $ - $ 570 $ 570 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return swaps - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576

Debt (Tables)	3 Months Ended
Debt (Tables)	Apr. 01, 2023
Debt [Abstract]
Bank Credit Lines	April 1, December 31, 2023 2022 Revolving credit agreement $ - $ - Other short-term bank credit lines 236 103 Total $ 236 $ 103
Long-Term Debt	April 1, December 31, 2023 2022 Private placement facilities $ 699 $ 699 U.S. trade accounts receivable securitization 360 330 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 3.65 % at April 1, 2023 and ranging from 0.00 % to 3.50 % at December 31, 2022 8 7 Finance lease obligations 9 10 Total 1,076 1,046 Less current maturities (55) (6) Total long-term debt $ 1,021 $ 1,040
Private Placement Facility Borrowings	Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 Less: Deferred debt issuance costs (1) Total $ 699

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Plan of Restructuring (Tables)	3 Months Ended
Plan of Restructuring (Tables)	Apr. 01, 2023
Plan of Restructuring [Abstract]
Schedule of Restructuring Costs	Three Months Ended April 1, 2023 Health-Care Distribution Technology and Value-Added Services Total Severance and employee-related costs $ 17 $ 3 $ 20 Accelerated depreciation and amortization 7 - 7 Exit and other related costs 1 1 2 Loss on disposal of a business 1 - 1 Total restructuring costs $ 26 $ 4 $ 30
Schedule of Restructuring Reserve by Segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 31, 2022 $ 21 $ 3 $ 24 Restructuring costs 26 4 30 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (7) - (7) Cash payments and other adjustments (14) (3) (17) Balance, April 1, 2023 $ 26 $ 4 $ 30

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Apr. 01, 2023
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,117,574 $ 71.38 Granted - - Exercised (10,897) 62.71 Forfeited (5,911) 77.31 Outstanding at end of period 1,100,766 $ 71.44 8.3 $ 13 Options exercisable at end of period 572,132 $ 68.11
Intrinsic Values	Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 520,781 $ 75.22 8.5 $ 4
Status of Unvested RSUs	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,756,044 $ 66.59 520,916 $ 60.23 Granted 395,750 77.75 465,260 79.66 Vested (387,302) 61.13 (627,596) 60.66 Forfeited (34,843) 68.16 (39,463) 74.48 Outstanding at end of period 1,729,649 $ 70.38 $ 81.54 319,117 $ 68.96 $ 81.54

Redeemable Noncontrolling Interests (Tables)	3 Months Ended
Redeemable Noncontrolling Interests (Tables)	Apr. 01, 2023
Redeemable Noncontrolling Interests [Abstract]
Components of the Change in Redeemable Noncontrolling Interests	April 1, December 31, 2023 2022 Balance, beginning of period $ 576 $ 613 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (8) (31) Increase in redeemable noncontrolling interests due to business acquisitions 3 4 Net income attributable to redeemable noncontrolling interests 4 21 Dividends declared (4) (21) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests 2 (6) Change in fair value of redeemable securities (3) (4) Balance, end of period $ 570 $ 576

Comprehensive Income (Tables)	3 Months Ended
Comprehensive Income (Tables)	Apr. 01, 2023
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss Net of Applicable Taxes	April 1, December 31, 2023 2022 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (35) $ (37) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (213) $ (236) Unrealized gain from foreign currency hedging activities 2 5 Pension adjustment loss (2) (2) Accumulated other comprehensive loss $ (213) $ (233) Total Accumulated other comprehensive loss $ (249) $ (271)
Components of Comprehensive Income, Net of Applicable Taxes	Three Months Ended April 1, March 26, 2023 2022 Net income $ 128 $ 186 Foreign currency translation gain 25 3 Tax effect - - Foreign currency translation gain 25 3 Unrealized gain (loss) from foreign currency hedging activities (4) 2 Tax effect 1 (1) Unrealized gain (loss) from foreign currency hedging activities (3) 1 Comprehensive income $ 150 $ 190
Total Comprehensive Income, Net of Applicable Taxes	Three Months Ended April 1, March 26, 2023 2022 Comprehensive income attributable to Henry Schein, Inc. $ 141 $ 184 Comprehensive income attributable to noncontrolling interests 3 1 Comprehensive income attributable to Redeemable noncontrolling interests 6 5 Comprehensive income $ 150 $ 190

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Apr. 01, 2023
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Three Months Ended April 1, March 26, 2023 2022 Basic 131,365,789 137,296,581 Effect of dilutive securities: Stock options and restricted stock units 1,674,097 1,940,891 Diluted 133,039,886 139,237,472
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended April 1, March 26, 2023 2022 Stock options 422,190 76,597 Restricted stock units 18,305 70,923 Total anti-dilutive securities excluded from EPS computation 440,495 147,520

Supplemental Cash Flow Information (Tables)	3 Months Ended
Supplemental Cash Flow Information (Tables)	Apr. 01, 2023
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Three Months Ended April 1, March 26, 2023 2022 Interest $ 13 $ 8 Income taxes 21 21

Basis of Presentation - Narrative (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Apr. 01, 2023	Dec. 31, 2022
Asset Pledged as Collateral [Member]
Pledged assets	$ 555	$ 327
Recourse [Member]
Liabilities of VIE	$ 420	$ 255

Net Sales from Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Contract with Customer, Liability, Current	$ 85	$ 86
Contract with Customer, Liability, Noncurrent	9	$ 8
Contract with Customer, Liability, Revenue Recognized	$ 35

Net Sales from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Disaggregation of Revenue [Abstract]
Net sales	$ 3,060	$ 3,179
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,261	2,411
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	799	768
Health-Care Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,869	3,000
Health-Care Distribution [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,095	2,255
Health-Care Distribution [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	774	745
Health-Care Distribution [Member] \| Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,898	1,828
Health-Care Distribution [Member] \| Dental [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,144	1,105
Health-Care Distribution [Member] \| Dental [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	754	723
Health-Care Distribution [Member] \| Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	971	1,172
Health-Care Distribution [Member] \| Medical [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	951	1,150
Health-Care Distribution [Member] \| Medical [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	20	22
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	191	179
Technology and Value-Added Services [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	166	156
Technology and Value-Added Services [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 25	$ 23

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Segment Data (Details) $ in Millions	3 Months Ended
Segment Data (Details) $ in Millions	Apr. 01, 2023 USD ($) segments countries	Mar. 26, 2022 USD ($)
Segment Data [Abstract]
Number of reportable segments \| segments	2
Segment Reporting Information [Line Items]
Net sales	$ 3,060	$ 3,179
Operating income	175	244
Health-Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	2,869	3,000
Operating income	$ 145	211
Number of countries served globally \| countries	32
Health-Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,898	1,828
Health-Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales	971	1,172
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	191	179
Operating income	$ 30	$ 33

Business Acquisitions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Business Acquisition [Line Items]
Acquisition costs	$ 7	$ 1
Series Of Individually Immaterial Business Acquisitions [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 1
Estimated useful lives (in years)	2 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 1
Estimated useful lives (in years)	5 years

Business Acquisitions - Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Dec. 31, 2022
Acquisition consideration:
Noncontrolling interests	$ 3
Identifiable assets acquired and liabilities assumed:
Goodwill	2,917	$ 2,893
Series Of Individually Immaterial Business Acquisitions [Member]
Acquisition consideration:
Cash	8
Deferred consideration	1
Noncontrolling interests	2
Total consideration	11
Identifiable assets acquired and liabilities assumed:
Intangible assets	2
Total identifiable net assets	2
Goodwill	9
Total net assets acquired	$ 11

Fair Value Measurements (Details) - USD ($) $ in Millions	Apr. 01, 2023	Dec. 31, 2022	Dec. 25, 2021
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 570	$ 576	$ 613
Estimate of Fair Value Measurement [Member]
Debt Instrument, Fair Value Disclosure [Abstract]
Fair value of debt (including bank credit lines)	1,312	1,149
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	23	27
Liabilities [Abstract]
Total liabilities	3	7
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	570	576
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	19	23
Liabilities [Abstract]
Derivative contracts - liabilities	1	1
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	3	4
Liabilities [Abstract]
Derivative contracts - liabilities	2	3
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps	1
Liabilities [Abstract]
Total return swaps		3
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps	0
Liabilities [Abstract]
Total return swaps		0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	23	27
Liabilities [Abstract]
Total liabilities	3	7
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	19	23
Liabilities [Abstract]
Derivative contracts - liabilities	1	1
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	3	4
Liabilities [Abstract]
Derivative contracts - liabilities	2	3
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps	1
Liabilities [Abstract]
Total return swaps		3
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	570	576
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps	$ 0
Liabilities [Abstract]
Total return swaps		$ 0

Debt - Bank credit lines (Details) - USD ($) $ in Millions	Apr. 01, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Bank Credit lines	$ 236	$ 103
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	0	0
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 236	$ 103

Debt - Revolving Credit Agreement and Other Short-Term Credit Lines Narrative (Details) - USD ($)	3 Months Ended
	Apr. 01, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Bank credit lines	$ 236,000,000	$ 103,000,000
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date	Aug. 20, 2021
Revolving credit facility borrowing capacity	$ 1,000,000,000.0
Revolving credit facility expiration date	Aug. 20, 2026
Borrowings	$ 0	0
Outstanding letters of credit provided to third parties	9,000,000	9,000,000
Bank credit lines	0	0
Revolving Credit Facility Maturing in April 2022 [Member]
Line of Credit Facility [Line Items]
Revolving credit facility borrowing capacity	750,000,000
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Revolving credit facility borrowing capacity	404,000,000	402,000,000
Bank credit lines	$ 236,000,000	$ 103,000,000
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)	7.55%	10.11%

Debt - Long-term Debt (Details) - USD ($) $ in Millions	Apr. 01, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Finance lease obligations	$ 9	$ 10
Total	1,076	1,046
Less current maturities	(55)	(6)
Long-term debt	1,021	1,040
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Long-term debt	699	699
U.S. Trade Accounts Receivable Securitization [Member]
Debt Instrument [Line Items]
Long-term debt	360	330
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 8	$ 7
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Borrowing Rate	0.00%	0.00%
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Borrowing Rate	3.65%	3.50%

Debt - Private Placement Facilities Narrative (Details) - Private Placement Facilities [Member]	3 Months Ended
	Apr. 01, 2023 USD ($)
Debt Instrument [Line Items]
Number of companies included in private placement facilities	4
Debt instrument maximum borrowing capacity	$ 1,500,000,000
Debt instrument, maturity date	Oct. 20, 2026
Average term of issuances under private placement facilities	12 years
Weighted average interest rate on borrowings under credit lines at period end (as a percent)	2.99%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years

Debt - Private Placement Facility Borrowings (Details) - Private Placement Facilities [Member] - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1)
Total	$ 699	$ 699
Debt Instrument, Maturity Date	Oct. 20, 2026
Private Placement Facilities Maturing in January 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 20, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3.45%
Debt Instrument, Maturity Date	Jan. 20, 2024
Private Placement Facilities Maturing in December 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Dec. 24, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3.00%
Debt Instrument, Maturity Date	Dec. 24, 2024
Private Placement Facilities Maturing in June 2027 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 16, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.42%
Debt Instrument, Maturity Date	Jun. 16, 2027
Private Placement Facilities Maturing in September 2029 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 15, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.52%
Debt Instrument, Maturity Date	Sep. 15, 2029
Private Placement Facilities Maturing in January 2028 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 02, 2018
Long-term Debt, Gross	$ 100
Borrowing Rate	3.32%
Debt Instrument, Maturity Date	Jan. 02, 2028
Private Placement Facilities Maturing in September 2030 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 02, 2020
Long-term Debt, Gross	$ 100
Borrowing Rate	2.35%
Debt Instrument, Maturity Date	Sep. 02, 2030
Private Placement Facilities Maturing in June 2031 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.48%
Debt Instrument, Maturity Date	Jun. 02, 2031
Private Placement Facilities Maturing in June 2033 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.58%
Debt Instrument, Maturity Date	Jun. 02, 2033

Debt - U.S. Trade Accounts Receivable Securitization Narrative (Details) - U.S. Trade Accounts Receivable Securitization [Member]	3 Months Ended	12 Months Ended
	Apr. 01, 2023 USD ($) number	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Debt instrument maximum borrowing capacity	$ 450,000,000
Long-term debt	$ 360,000,000	$ 330,000,000
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)	0.30%
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)	0.35%
Number of banks as agents for debt instrument \| number	2
Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate at period end	5.74%	5.33%
Debt instrument, variable rate basis at period end	4.99%	4.58%
Debt instrument, basis spread on variable rate	0.75%	0.75%

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Apr. 01, 2023	Mar. 26, 2022	Dec. 31, 2022
Income Tax Examination [Line Items]
Effective tax rate	23.80%	24.00%
Tax interest expense (credit)	$ 1	$ 1
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	95		$ 94
Unrecognized tax benefits that would affect the effective tax rate if recognized	80		80
Total interest	$ 13		$ 12

Plan of Restructuring - Narrative (Details) - USD ($)	3 Months Ended
Plan of Restructuring - Narrative (Details) - USD ($)	Apr. 01, 2023	Mar. 26, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 30,000,000	$ 0
Disposal of Unprofitable U.S. Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,000,000

Plan of Restructuring - Schedule of Restructuring Costs (Details) - USD ($)	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 30,000,000	$ 0
Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	20,000,000
Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	7,000,000
Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,000,000
Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000
Health-Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	26,000,000
Health-Care Distribution [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	17,000,000
Health-Care Distribution [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	7,000,000
Health-Care Distribution [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000
Health-Care Distribution [Member] \| Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	4,000,000
Technology and Value-Added Services [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3,000,000
Technology and Value-Added Services [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0
Technology and Value-Added Services [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000
Technology and Value-Added Services [Member] \| Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 0

Plans of Restructuring and Integration Costs - Schedule of Restructuring Reserve by Segment (Details) - USD ($)	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Restructuring Cost and Reserve [Line Items]
Balance, beginning	$ 24,000,000
Restructuring costs	30,000,000	$ 0
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	(7,000,000)	$ 0
Payments and other adjustments	(17,000,000)
Balance, ending	30,000,000
Health-Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning	21,000,000
Restructuring costs	26,000,000
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	(7,000,000)
Payments and other adjustments	(14,000,000)
Balance, ending	26,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning	3,000,000
Restructuring costs	4,000,000
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	0
Payments and other adjustments	(3,000,000)
Balance, ending	$ 4,000,000

Legal Proceedings - Narrative (Details) $ in Millions	3 Months Ended
Legal Proceedings - Narrative (Details) $ in Millions	Apr. 01, 2023 USD ($) claims	Mar. 26, 2022 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 3,060	$ 3,179
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number \| claims	175
Actions Consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage	0.20%
Actions Consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 12,600
Other Hospitals Located throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs	38
DCH Health Care Authority, et al. [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs	38
Number of plaintiffs set for jury trial	8

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)	2 years 8 months 12 days
Grants in period (in shares)	0
Total unrecognized compensation cost related to non-vested awards	$ 119.0
Expected life of options (years)	6 years
After-tax share-based compensation (credit) expense	$ 7.0	$ 9.0
Pre-tax share-based compensation (Credit) expense	$ 10.0	$ 12.0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years
Percentage of stock options vest per year	33.33%
Expiration period (in years)	10 years
Time-Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	4 years
Time-Based Restricted Stock Restricted Units [Member] \| 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	12 months
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years

Stock-Based Compensation - Summary of Stock Option Activity under the Plans (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Apr. 01, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares) \| shares	1,117,574
Granted (in shares) \| shares	0
Exercised (in shares) \| shares	(10,897)
Forfeited (in shares) \| shares	(5,911)
Outstanding at end of period (in shares) \| shares	1,100,766
Weighted Average Exercise Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 71.38
Granted (in dollars per share) \| $ / shares	0
Exercised (in dollars per share) \| $ / shares	62.71
Forfeited (in dollars per share) \| $ / shares	77.31
Outstanding at end of period (in dollars per share) \| $ / shares	$ 71.44
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	8 years 3 months 18 days
Outstanding at end of period, Aggregate Intrinsic Value \| $	$ 13
Options exercisable (in shares) \| shares	572,132
Weighted average exercise price, options exercisable (in dollars per share) \| $ / shares	$ 68.11

Disclosure - Stock-Based Compensation - Intrinsic Values (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Apr. 01, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	520,781
Weighted Average Exercise Price \| $ / shares	$ 75.22
Weighted Average Remaining Contractual Life (in years)	8 years 6 months
Aggregate Intrinsic Value \| $	$ 4

Stock-Based Compensation - Status of Unvested RSUs (Details)	3 Months Ended
	Apr. 01, 2023 $ / shares shares
Time-Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,756,044
Granted (in shares) \| shares	395,750
Vested (in shares) \| shares	(387,302)
Forfeited (in shares) \| shares	(34,843)
Ending balance outstanding (in shares) \| shares	1,729,649
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 66.59
Granted (in dollars per share)	77.75
Vested (in dollars per share)	61.13
Forfeited (in dollars per share)	68.16
Ending balance outstanding (in dollars per share)	70.38
Aggregate intrinsic value	$ 81.54
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	520,916
Granted (in shares) \| shares	465,260
Vested (in shares) \| shares	(627,596)
Forfeited (in shares) \| shares	(39,463)
Ending balance outstanding (in shares) \| shares	319,117
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 60.23
Granted (in dollars per share)	79.66
Vested (in dollars per share)	60.66
Forfeited (in dollars per share)	74.48
Ending balance outstanding (in dollars per share)	68.96
Aggregate intrinsic value	$ 81.54

Redeemable Noncontrolling Interests - Components of the Change in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Apr. 01, 2023	Mar. 26, 2022	Dec. 31, 2022
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period	$ 576	$ 613	$ 613
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interest in subsidiaries	(8)		(31)
Increase in redeemable noncontrolling interests due to business acquisitions	3		4
Net income attributable to redeemable noncontrolling interests	4	4	21
Dividends declared	(4)		(21)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	2	$ 1	(6)
Change in fair value of redeemable securities	(3)		(4)
Balance, end of period	$ 570		$ 576

- Definition

Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022	Dec. 31, 2022
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (35)		$ (37)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(1)		(1)
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(213)		(236)
Unrealized gain from foreign currency hedging activities	2		5
Pension adjustment loss	(2)		(2)
Accumulated other comprehensive loss	(213)		(233)
Total Accumulated other comprehensive loss	(249)		$ (271)
Components of Comprehensive Income
Net Income (loss)	128	$ 186
Foreign currency translation gain	25	3
Tax effect	0	0
Foreign currency translation gain	25	3
Unrealized gain (loss) from foreign currency hedging activities	(4)	2
Tax effect	1	(1)
Unrealized gain (loss) from foreign currency hedging activities	(3)	1
Comprehensive income	$ 150	$ 190

Comprehensive Income - Total Comprehensive Income, Net of Applicable Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 141	$ 184
Comprehensive income attributable to noncontrolling interests	3	1
Comprehensive income attributable to Redeemable noncontrolling interests	6	5
Comprehensive income	$ 150	$ 190

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

Earnings Per Share - Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted (Details) - shares	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Weighted-average common shares outstanding:
Basic (in shares)	131,365,789	137,296,581
Effect of dilutive securities:
Stock options and restricted stock units	1,674,097	1,940,891
Diluted (in shares)	133,039,886	139,237,472

Earnings Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	440,495	147,520
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	422,190	76,597
Restricted Stock Units R S U [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	18,305	70,923

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022
Supplemental Cash Flow Information [Abstract]
Interest	$ 13	$ 8
Income taxes	21	21
Non-cash net unrealized gains related to foreign currency hedging activities	$ (4)	$ 2

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 01, 2023	Mar. 26, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Current operating lease liabilities	$ 73		$ 73
Noncurrent operating lease liabilities	274		275
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Due to related party	6		6
Due from related party	34		36
Revenue from Related Parties	8	$ 12
Related Party Transaction, Purchases from Related Party	$ 2	4
Internet Brands Inc [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Period Covered By Agreement	10 years
Related Party Transaction, Expenses from Transactions with Related Party	$ 8	$ 9
Due to related party	31
Related Party Transaction, Due from (to) Related Party	12		$ 8
Employees and Minority Shareholders [Member]
Related Party Transaction [Line Items]
Current operating lease liabilities	4
Noncurrent operating lease liabilities	$ 15
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage	6.10%
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Non-Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage	5.60%
Employees and Minority Shareholders [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	1 year
Employees and Minority Shareholders [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	9 years